A novel comparison of stentless versus stented valves in the small aortic root  by Rao, Vivek et al.
dients after surgery, which may adversely affect the
regression of left ventricular mass and lead to lower
long-term survival.5 Surgeons have intuitively attempt-
ed to insert the largest valve possible for any given
annular dimension. The industry-labeled valve size is
meant to provide information enabling the surgeon to
judge whether an implanted valve is of adequate size for
the patient.6 Experienced surgeons can then decide to
choose a different prosthesis, perform an annular en-
larging procedure,3 or alternatively insert the valve in a
supra-annular position.
When comparing bioprostheses from different manu-
facturers, most authors have stratified their analyses on
the basis of the industry-labeled valve size.7-10
Unfortunately, recent reports have demonstrated a dis-
crepancy between the labeled valve size and the actual
dimensions of the valve or its sizer.11,12 Furthermore, in
a previous study we demonstrated that the industry-
labeled valve size bore no relation to any hemodynam-
ically significant dimension and varied considerably
among manufacturers.13 For example, the internal
T he results of aortic valve replacement may beadversely affected by patient-prosthesis mismatch,
especially in patients with small aortic roots.1-4 The
poorer results may be due to residual postoperative gra-
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A NOVEL COMPARISON OF STENTLESS VERSUS STENTED VALVES IN THE SMALL AORTIC ROOT
diameter of a 25-mm Toronto stentless porcine valve
(SPV; St Jude Medical, Inc, St Paul, Minn) is 21 ± 2
mm compared with 24 ± 1 mm for a 25-mm
Carpentier-Edwards stented pericardial valve (CEP;
Baxter Healthcare Corp, Edwards Division, Irvine,
Calif). An internal diameter of 21 mm would roughly
correspond to a size 21 CEP valve. Similarly, a 25-mm
SPV has a measured external diameter of 25 ± 1 mm
compared with 32 ± 1 mm for a 25-mm CEP valve.
Therefore we believe that it is meaningless to perform
hemodynamic comparisons between prosthetic valves
on the basis of the manufacturer’s labeled valve sizes.
This study presents a hemodynamic comparison of the
SPV versus the CEP valve based on measured internal
diameters. We chose to restrict our comparison to
patients with small aortic roots because differences in
valvular performance are most likely to affect out-
comes in this high-risk subgroup.
Methods
We reviewed the case histories of all patients who under-
went isolated aortic valve replacement (with or without coro-
nary artery bypass grafting) and received either a Toronto
SPV or a CEP valve between December 1, 1989, and October
1, 1997 (n = 236). There were 110 patients who received
either an SPV (n = 41 of 133, 31%) or a CEP (n = 69 of 103,
67%) with a measured internal diameter of less than 22 mm.
Fig 1 illustrates the distribution of valve sizes and measured
internal diameters for each group.
A valvular database currently used at Sunnybrook Health
Science Centre was used to collect preoperative, periopera-
tive, and postoperative data on all patients in a prospective
fashion. Clinical data were obtained prospectively on all 110
patients with a mean follow-up of 18 ± 15 months (range 1-
60 months). Seven patients were lost to follow-up, of whom
4 were seen 1 year after the operation for their echocardio-
graphic examination. Thus 1-year follow-up data are avail-
able on 103 of the original 110 patients (97%).
The study protocol was approved by the Institutional
Review Board of the Sunnybrook Health Science Centre.
Patients who received the SPV during the investigational
phase of the valve provided written, informed consent.
Eligible patients received a bioprosthetic valve (for medical
or lifestyle reasons) and were considered for either a stentless
or stented valve. Patients with a greater than 10% discrepan-
cy between the measured aortic anulus and the sinotubular
junction were considered to be ineligible candidates for the
SPV, as were patients with extensive calcific disease. The
study population includes patients who are currently enrolled
in a prospective, randomized trial comparing the SPV and
CEP valves.
Operative technique. We have previously described our
surgical and anesthetic techniques in detail.5 The technique
for sizing and implanting valves including the Toronto SPV
bioprosthesis has been well documented previously.14,15 All
patients with documented coronary artery disease underwent
concomitant revascularization at the time of aortic valve
replacement. To maximize external validity, surgeons were
permitted to use their preferred cardiopulmonary bypass and
cardioplegic methods, which remained identical for each
valve procedure.
Echocardiographic measurements. Echocardiography
was performed before the operation, 3 to 6 months, and 12 to
15 months after the operation. Thirty-four (80%) patients in
the SPV group and 33 (41%) patients in the CEP group had
echocardiographic data at all time points. Examination
included 2-dimensional, 2-dimensional derived M-mode,
continuous wave, and pulsed Doppler and color Doppler
analyses done with a Hewlett-Packard Sonos 1000 E echocar-
diographic machine (Hewlett-Packard Company, Andover,
Mass) with a 2.5-MHz transducer. Left parasternal, apical,
periapical, right parasternal, subcostal, and suprasternal stan-
dard views were obtained in a step-by-step successive pattern
of interrogation. All measurements were averaged from 3 car-
diac cycles in sinus rhythm and performed by only 2 sonog-
raphers who were previously assessed and confirmed for less
than 5% interobserver variability.5
Left ventricular mass was calculated from 2-dimensional
derived M-mode measurements taken according to the
American Society of Echocardiography recommendations.
Left ventricular mass indexed on body surface area (LVMI)
provides a noninvasive and highly reproducible estimate of
the extent of left ventricular hypertrophy. LVMI is a reflec-
tion of the severity of aortic stenosis and has been positively
correlated to peak aortic valve gradients.16 LVMI has previ-
ously been shown to regress early after aortic valve replace-
ment, but residual left ventricular hypertrophy is present in
most patients and may be related to the presence of a rela-
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Fig 1. Distribution of valve sizes among 110 patients receiv-
ing small aortic bioprostheses. Left panel, Distribution of
valves implanted based on manufacturer’s labeled size. Right
panel, Distribution of valves implanted based on measured
internal diameter. The apparent discrepancy in valve sizes
between groups is resolved when internal diameter is taken
into consideration.
tively stenotic aortic valve prosthesis.5,17,18 Measurements of
effective orifice area, peak and mean transvalvular pressure
gradients, and LVMI were calculated with the use of previ-
ously published formulas.14
Statistical analysis. Statistical analyses were performed
with the use of the SAS program (SAS Institute, Inc, Cary,
NC). Perioperative demographics were compared by means
of c 2 or Fisher’s exact test for categoric variables and analy-
sis of variance (ANOVA) for continuous variables.
Hemodynamic comparisons between prosthetic groups were
performed by means of 2-way repeated-measures ANOVA
with the main effects of time, group, and internal diameter on
each outcome. Continuous data are presented as the mean ±
SD with figures illustrating standard error bars. Actuarial sur-
vival was calculated by means of the Kaplan-Meier method
with Mantel-Cox regression analysis to compare survival
between groups and illustrated as smoothed estimates of sur-
vival at 6-month intervals after the operation. Exact P values
are provided for each comparison.
Results
Patient population. Table I illustrates the preopera-
tive patient demographics for each group. Patients in
the SPV group were younger (62 ± 14 vs 75 ± 6 years,
P = .0001) and were less likely to undergo simultane-
ous coronary revascularization. There were no signifi-
cant differences in gender, preoperative left ventricular
function, aortic valve disease, or body surface area.
Perioperative clinical outcomes. Table II summa-
rizes the intraoperative and early postoperative data.
The aortic occlusion and cardiopulmonary bypass times
were similar in each group. No deaths occurred in the
SPV group, whereas 6 deaths occurred in the CEP
group (P = .06). Ventilation requirements were signifi-
cantly shorter in the SPV group (14 ± 11 hours, range 3-
68 hours) than in the CEP group (24 ± 41 hours, range
3-266 hours). Similarly, postoperative length of stay
was shorter in the SPV group (8 ± 5 days, range 4-28
days, vs 11 ± 7 days, range 5-43 days; P = .05). Fig 2
illustrates actuarial survival in both groups (inclusive of
perioperative mortality). At 36 months, survival in the
CEP group was 80% ± 6% compared with 91% ± 5% in
the SPV group (P = .055 by Wilcoxon). There were 3
late deaths in the SPV group, all due to complications of
stroke. There were 4 late deaths in the CEP group. Two
late deaths in the CEP group were due to complications
of stroke and 1 was due to a myocardial infarction. The
fourth late death occurred in a patient who underwent
reoperation for prosthetic valve endocarditis 14 months
after the initial operation.
Postoperative hemodynamics. Fig 3 illustrates the
mean pressure gradient for each valve group with time.
No significant differences in mean pressure gradient
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Fig 2. Actuarial survival in patients receiving a Toronto SPV
or a CEP valve. Cox-Wilcoxon regression analysis demon-
strates a significant difference in actuarial survival (P = .055).
Table I. Preoperative clinical information 
SPV CEP 
(n = 41) (n = 69) P value
Elderly (>70 y) 13 (32) 58 (84) .001
Female sex 28 (68) 35 (51) .07
LVEF < 40% 2 (5) 10 (14) .12
Concomitant revascularization 13 (32) 40 (58) .008
Redo sternotomy 1 (2) 6 (9) .25
Aortic valve disease .70
Stenosis 30 (73) 47 (68)
Regurgitation 3 (7) 11 (16)
Mixed disease 8 (20) 9 (13)
Prosthetic valve dysfunction 0 (0) 2 (3)
Body surface area (m2 ± SD) 1.8 ± 0.2 1.8 ± 0.2 .76
Number and percentages (parentheses). LVEF, Left ventricular ejection fraction.
Table II. Perioperative data
SPV CEP 
(n = 41) (n = 69) P value
Aortic crossclamp time (min) 125 ± 24 116 ± 34 .17
Cardiopulmonary bypass time 148 ± 30 151 ± 48 .74
(min)
Postoperative stroke, No. (%) 1 (2) 4 (6) .65
Permanent cardiac pacing, No. 1 (2) 9 (13) .09
(%)
Blood transfusion, No. (%) 40 (98) 63 (91) .25
Ventilation requirements (h) 14 ± 11 27 ± 42 .02
ICU stay (h) 51 ± 50 51 ± 44 .99
Postoperative stay (d) 8 ± 5 10 ± 7 .05
Operative mortality, No. (%) 0 (0) 6 (9) .06
Results are expressed as mean ± SD unless otherwise specified; Fisher’s exact
test for categoric values, the Student t test for continuous variables. ICU,
Intensive care unit.
were noted between groups at any time point.
Repeated-measures ANOVA demonstrated no interac-
tive effect between group and time, a significant
decrease in mean gradient with time (time effect: F =
68, P = .0001), but no significant differences resulting
from group (group effect: F = 2, P = .15) or internal
diameter (size effect: F = 1.14, P = .29). Fig 4 demon-
strates calculated effective orifice areas for each valve
group over time. There was no interactive effect
between group and time, nor were there significant dif-
ferences in calculated effective orifice areas between
groups (group effect: F = 0.63, P = .43). However,
repeated-measures ANOVA demonstrated a significant
time effect (F = 58, P = .0001) and size effect (F = 11.7,
P = .009). Figs 5 and 6 illustrate the regression in
LVMI with time after aortic valve replacement. There
was a significant reduction in LVMI in both groups
during the first 6 months after the operation, with little
further reduction occurring in the subsequent 6 months.
There were no significant interactive effects between
group and time. However, there was a significant effect
of internal diameter on the regression of LVMI (size
effect: F = 5.2, P = .02) and a significant difference
between groups (group effect: F = 15.8, P = .0001).
Table III illustrates a hemodynamic comparison
between a 25-mm SPV (21-mm internal diameter) and
a 21-mm CEP valve (20-mm internal diameter). At 6
months after the operation, there were no significant
differences in peak or mean systolic gradients nor in the
regression in LVMI. However, calculated effective ori-
fice areas were larger in the similarly sized SPV valves
(1.5 ± 0.3 cm2 vs 1.2 ± 0.3 cm2, P = .01).
Discussion
Aortic valve replacement remains the definitive treat-
ment for critical aortic stenosis and for aortic insuffi-
ciency with left ventricular dilatation. Unfortunately,
elderly patients with small aortic roots are at risk for
prosthesis-patient mismatch if they receive a conven-
tional stented bioprosthesis. Surgeons use the manufac-
turer’s labeled valve size as an index of the adequacy of
a prosthetic valve’s effective orifice area. Intuitively,
surgeons avoid inserting 19- or 21-mm bioprostheses in
patients with a body surface area above 1.7 m2.2,9,10
The alternatives to implanting a small bioprosthesis
include mechanical valve replacement, patch enlarge-
ment of the aortic anulus,3 or implantation of a stent-
less bioprosthesis.15,19 Mechanical valves have a pro-
portionally larger effective orifice area for a given
anulus size and have been shown to produce lower gra-
dients when compared with similarly sized bioprosthe-
ses.8,10 However, elderly patients are at increased risk
for anticoagulant-related hemorrhage; therefore
mechanical valve replacement may be inadvisable.
Sommers and David3 demonstrated that anulus-enlarg-
ing procedures resulted in long-term survivals compa-
rable with those of patients receiving larger aortic pros-
theses; however, the operative mortality of aortic valve
replacement increased from 3.5% to 7.1% when
enlargement of the aortic anulus was performed.
Sintek and colleagues20 implanted 27 Freestyle stent-
less porcine valves (Medtronic, Irvine, Calif) in
patients with small aortic anuli. At 1 year after the
operation, the mean systolic gradient ranged from 2.2
to 19.3 mm Hg for size 19- and 21-mm valves. These
results are similar to the findings of our present study.
However, to date no patient at our institution has
received a 19- or 21-mm SPV bioprosthesis. Sintek’s
group uses the subcoronary technique for implantation
of the Freestyle valve, which is the technique used to
implant the Toronto SPV bioprosthesis. Therefore, how
do surgeons compare the results of aortic valve replace-
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Fig 3. Mean systolic gradients after aortic valve replacement
with a Toronto SPV or a CEP valve.
Fig 4. Calculated effective orifice areas after aortic valve
replacement with a Toronto SPV or a CEP valve. 
ment in small aortic roots when one center is implant-
ing 23- and 25-mm SPV bioprostheses and another
center is implanting 19- and 21-mm Freestyle valves?
It would appear logical that implantation of a larger
valve should result in improved postoperative hemody-
namics, but our gradients are similar to those reported
by Sintek and colleagues.19,20 The explanation for this
apparent discrepancy is that the internal diameter of a
19-mm Medtronic Freestyle valve is similar to that of a
23-mm Toronto SPV bioprosthesis. When one com-
pares valves on the basis of measured internal diame-
ters, the hemodynamic parameters more closely reflect
the intrinsic properties of the valve versus confounding
effects resulting from an arbitrary manufacturer-based
labeling system.
Fig 1 provides further evidence to support the dis-
crepancy between labeled valve sizes and measured
internal diameters. The left panel would suggest that in
this nonrandomized cohort, we were selectively insert-
ing larger valves in the SPV group. In fact, previous
publications from our group and others have consis-
tently found that the SPV valve “allowed” for the
implantation of a 2- to 4-mm larger valve.5,14,15
However, the right panel of Fig 1 clearly indicates that
similar sized valves were implanted in both groups.
Furthermore, the CEP and other stented valves can be
potentially inserted in a supra-annular position, allow-
ing the bulk of cuff tissue to fill the aortic sinuses. Thus
it is possible to implant a Toronto SPV and a CEP valve
with dissimilar external diameters, but similar internal
diameters, into the same anulus. The external diameter
in this situation would not accurately reflect the size of
the valve being implanted and may not predict postop-
erative gradients. We believe that the internal diameter
is the only consistent, reproducible measurement that
can allow for accurate hemodynamic comparisons
between valves.
In this study, we compared the SPV and CEP valves
on the basis of internal diameters. Thus 23- and 25-mm
Toronto SPV bioprostheses (manufacturer’s sizes) were
compared with 19-, 21-, and 23-mm CEP valves. The
mean labeled size implanted in each group was signifi-
cantly larger for SPV bioprostheses (24.2 ± 1 vs 21.9 ±
1, P < .001). In contrast, the mean internal diameter was
The Journal of Thoracic and
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Fig 5. LVMI after aortic valve replacement with a Toronto
SPV or a CEP valve. There was a significant reduction in
LVMI in both groups during the first 6 months after the oper-
ation with little further reduction occurring in the ensuing 6
months.
Fig 6. The regression in LVMI after aortic valve replacement
with a Toronto SPV or a CEP valve. There was a significant
regression in LVMI in both groups during the first 6 months
after the operation with little further reduction occurring in
the ensuing 6 months. 
Table III. Postoperative hemodynamic data for 25-mm
Toronto SPV (21-mm internal diameter) and 21-mm
CEP valve (20-mm internal diameter)
25-mm SPV 21-mm CEP 
(n = 26) (n = 29) P value
Peak systolic gradient (mm Hg)
Preoperative 53 ± 32 59 ± 23 .69
Six months 18 ± 7 17 ± 4 .69
One year 18 ± 6 21 ± 6 .26
Mean systolic gradient (mm Hg)
Preoperative 34 ± 33 36 ± 17 .88
Six months 10 ± 5 9 ± 4 .45
One year 9 ± 6 12 ± 5 .23
Effective orifice area (cm2)
Preoperative 1.0 ± 0.4 0.8 ± 0.3 .26
Six months 1.5 ± 0.3 1.2 ± 0.3 .01
One year 1.6 ± 0.3 1.3 ± 0.2 .03
LVMI
Preoperative 136 ± 36 115 ± 29 .08
Six months 110 ± 23 107 ± 35 .84
One year 109 ± 26 105 ± 24 .66
Results are expressed as mean ± SD.
larger in the CEP group (20.9 ± 0.3 vs 20.2 ± 1.0, P =
.009). All of these valves have internal diameters rang-
ing from 18 to 22 mm. In contrast, the external diame-
ter for the SPV bioprostheses studied in this series
ranged from 23 to 25 mm compared with 26 to 30 mm
for the CEP valves. For a “labeled” valve size of 23 mm,
the difference in external diameter between groups is 7
mm. One would expect that such a large discrepancy
would result in significant hemodynamic differences
between groups. The fact that there were no differences
in gradients between groups lends further evidence to
our contention that the internal diameter of a prosthetic
valve is the most important predictor of postoperative
hemodynamics. Furthermore, a supra-annular implanta-
tion of a 21-mm CEP valve would yield a larger internal
diameter than a subcoronary implantation of a 23-mm
SPV bioprosthesis. Thus implantation of a 23-mm valve
(manufacturer’s label) in a patient with a large body sur-
face area does not preclude patient-prosthesis mismatch
unless the internal diameter of the valve being implant-
ed is taken into consideration.
Our analyses revealed that patients who received a
“small-sized” 25-mm Toronto SPV bioprosthesis dis-
played significantly greater effective orifice areas with
time. Despite this increase in effective orifice area,
there were no appreciable differences in gradients or
mass regression. The calculated power to detect a dif-
ference at the 5% a -level was relatively high: 93%
power to detect a 5-mm difference in peak gradient;
91% to detect a 3-mm difference in mean gradient;
98% to detect a 20 g/m2 difference in left ventricular
mass, and 99% to detect a 0.1 cm2 difference in effec-
tive orifice area.
However, this report and previous studies from other
investigators have demonstrated superior clinical
results in patients receiving the SPV bioprosthesis.14,15
Because of the investigational nature of our early expe-
rience with this valve, it is possible that differences in
clinical outcomes may be simply due to patient selec-
tion. Patients who received SPV bioprostheses were
younger and were less likely to require myocardial
revascularization. As a result, despite the more techni-
cally demanding implantation of an SPV bioprosthesis,
overall aortic occlusion and cardiopulmonary bypass
times were not different between groups. Additional
follow-up is required to determine whether the
observed survival benefit persists with time. David and
associates21 recently reported a case-matched cohort
study that demonstrated improved survival in patients
who received an SPV bioprosthesis. We are currently
involved in a prospective randomized clinical trial com-
paring the SPV and CEP valves with respect to hemo-
dynamic parameters. The randomized design of this
study should provide further information with regard to
a potential survival benefit among patients who receive
a stentless valve.
The ability of a stentless valve to allow dynamic expan-
sion of the aortic root may be the mechanism resulting in
increased effective orifice areas. Further study is required
to determine whether this property of stentless valves
allows for implantation of small valves in small anuli
with no adverse hemodynamic or clinical sequelae.
Our study is limited by the relatively small sample
size and short follow-up. Unfortunately, small aortic
valves are implanted in fewer than 50% of patients
undergoing aortic valve replacement. Furthermore, the
retrospective nature of this study introduces potential
bias despite the fact that all clinical and hemodynamic
data were collected prospectively as part of our routine
valvular follow-up.
Our arbitrary cut point for the internal diameter
resulted in the inclusion of 23-mm CEP valves and the
exclusion of 27-mm SPV bioprostheses (labeled sizes).
The size ranges defined in this study included 31% of
all SPV bioprostheses implanted compared with 67%
of all CEP valves inserted during the same period. This
may have biased the hemodynamic results against the
SPV bioprosthesis as the average internal diameter was
larger in the CEP group. However, the direct compari-
son based on internal diameter (Table III) demonstrates
the expected result that similar sized valves produce
similar postoperative hemodynamics. 
In summary, we conclude that hemodynamic com-
parisons between prosthetic valves are inaccurate if
based solely on the manufacturer’s labeled size. More
meaningful comparisons can be made prospectively if
surgeons compare the actual size of different valvular
substitutes that they would implant in a given patient.
However, this decision is highly surgeon-specific and
may be influenced by a surgeon’s willingness to per-
form an anulus-enlarging procedure or to implant the
valve in a supra-annular position. Given these short-
comings, we believe that the most reliable and repro-
ducible measurement of valve size remains the internal
diameter. We suggest that future comparisons of pros-
thetic valves should be based on this measure of valve
size such that differences between valves can be attrib-
uted to their intrinsic properties versus artifact caused
by arbitrary labeling.
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Discussion
Dr Colleen F. Sintek (Los Angeles, Calif). I would like to
congratulate the authors on once again contributing to our
understanding of valve sizing and hemodynamics.
Since the introduction of stentless valves, many authors
have reported on the excellent hemodynamics, with low
transvalvular gradients that increase only slightly with exer-
cise, and superior effective orifice areas.
The small nonrandomized study that you have presented
concludes that the Toronto SPV and the stented CEP valves
have similar hemodynamic profiles in the smaller valve sizes
when compared on the basis of internal diameter size.
I have several concerns regarding the conclusions. First, as
a practicing surgeon, I want to know what size of each pros-
thetic valve I can implant for a given anulus size. Therefore,
my first question is: Wouldn’t it be more appropriate to com-
pare valves on the basis of patient anulus size rather than
internal diameter?
Dr Rao. That’s an excellent question, and we are address-
ing that issue in a current, prospective trial. We believe that
the most accurate method to compare valve sizes is to ask the
surgeon, who remains blinded to valve group before inser-
tion, which valve size in each group would he or she insert on
the basis of the patient’s anulus. Unfortunately, this compari-
son is confounded between surgeons and between centers in
that some surgeons may elect to do a supra-annular insertion
of a given valve to increase the implanted size. In contrast, a
different surgeon may elect to perform an anulus-enlarging
procedure. Given these shortcomings, we believe that the
only reliable indicator of postoperative hemodynamics com-
parable across centers and across surgeons is the internal
diameter of the valve. This measurement is not affected by
the site at which the valve is inserted within the outflow tract,
and it represents the maximal orifice area that can be
achieved in that patient.
Dr Sintek. In a patient in whom you can implant a size 25
SPV bioprosthesis, would that patient receive a size 21 peri-
cardial valve, or would he or she receive a larger size or a
smaller size pericardial valve?
Dr Rao. Given an identical root, where both the SPV and
a stented valve can be placed, our data would suggest that a
23-mm stented valve would yield a larger internal diameter
than a 25-mm SPV bioprosthesis. The surgeon may have to
resort to implanting the stented valve in a supra-annular posi-
tion to safely accommodate a 23-mm prosthesis. A 21-mm
intra-annular stented valve would yield a similar internal
diameter to a 25-mm SPV bioprosthesis.
However, an important point is whether there is an intrin-
sic benefit to a stentless design that might lead to improved
postoperative hemodynamics. If a surgeon believes that the
benefits of a dynamic, expansile aortic root outweigh the
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small difference in valvular size, a stentless valve may be the
preferred prosthesis.
Dr Sintek. Am I correct that you ordinarily would upsize
by 2 mm on a stentless valve?
Dr Rao. That’s correct.
Dr Sintek. My second concern is that you have lumped all
the valve sizes of the Toronto SPV bioprosthesis as well as
the pericardial prosthesis together in your analysis. As you
stated in your manuscript and showed on one of your slides,
the data are actually biased in favor of the pericardial valve,
as more than 50% of the pericardial data were collected from
valves with a 22-mm internal diameter, larger than the
Toronto valves. I am not sure that your conclusion that the
valves are hemodynamically equivalent is correct. In fact,
when you matched internal diameters comparing the size 25
SPV bioprosthesis against the size 21 CEP valve, you did
show a larger effective orifice area with the Toronto valve. In
my interpretation of your left ventricular mass regression data
for those 2 valve sizes, the 25-mm SPV versus the 21-mm
CEP, there was significantly greater left ventricular mass
regression from 64-g decrease in the Toronto valve versus
only a 12-g decrease in the pericardial size 21 valve at 1
year’s follow-up. Could you comment on that?
Dr Rao. We agree with your conclusion. The basis of our
study design originated in previous studies in which we strat-
ified by labeled valve size. We found no differences in post-
operative gradients, yet there was a persistent difference in
effective orifice areas and left ventricular mass regression.
The only way we could account for this was to assume that
valves with similar sized internal diameters would yield sim-
ilar peak and mean gradients and that the differences in effec-
tive orifice areas and the regression of left ventricular mass
were due to the effect of a rigid stent. I think we agree that
stentless valves have beneficial effects that are independent of
the fact that a larger valve can be inserted, because our data
show clearly that similar sized valves are being implanted.
Dr Sintek. My next concern is your analysis of your clini-
cal results. As you pointed out, there were no surgical deaths
in the Toronto group, yet 6 patients died in the pericardial
group. I am not sure that we can attribute this huge difference
to patient factors alone; in fact, they may very well be due to
valve-related factors. Certainly if you have a residual trans-
valvular gradient in the early postoperative period, these
patients may have low cardiac output syndrome and be prone
to the development of multiorgan system failure.
Did these deaths occur in the patients with smaller pericar-
dial valves, that is, the 19-mm valves?
Dr Rao. Most of the deaths actually occurred in patients
receiving the 21-mm CEP valves, and 4 of the 6 were due to
stroke. The 4 late deaths in the CEP group were due to stroke
(n = 2), myocardial infarction (n = 1), or endocarditis (n = 1).
Dr Sintek. Finally, you commented on the differences in
valve sizing between the Toronto and the Medtronic Freestyle
stentless valves. Over the past 51⁄2 years our group has
implanted more than 100 of the Freestyle valves. In 34 of our
patients we have implanted size 19 or 21 valves. In our expe-
rience we can always upsize by 2 mm; in other words, we
insert a 2-mm larger Freestyle valve on the basis of the man-
ufacturer’s labeled size as compared to any of the stented bio-
prostheses. For a size 21 valve, we get an effective orifice
area of 1.5 cm2, and with our sizing system that should be
compared with a 19-mm pericardial valve, because that is
what we can place in that given patient’s anulus. The effec-
tive orifice area for that valve is 1.1 cm2.
Thus, in these small valve sizes, I think the Medtronic
Freestyle valve definitely has better hemodynamics than the
pericardial valve, and it appears to have possibly better hemo-
dynamics than the Toronto valve. Could you comment on that?
Dr Rao. Our center does not have experience with the
Freestyle valve, but we certainly read with interest your work
in that area. Again, you ask which valve should be inserted in
a given patient’s anulus and what the surgeon would have to
do to insert a larger valve (ie, an anulus-enlarging procedure
or a supra-annular placement of the valve). To answer that
question, you have to know the intrinsic properties of the
valve. I think we both agree that if you know the internal
diameter of the valve that you are proposing to implant, then
you can make the best decision as to which valve, which size,
and which procedure you should do.
Dr Sintek. In your series you expressed the belief that a
calcified aortic root was a contraindication to placing a
Toronto SPV bioprosthesis. In our experience with the
Freestyle valve, we have in fact felt that patients who have
calcified aortic roots are ideal candidates, because the
Freestyle valve can be seated much more safely without the
possibility of disrupting the calcified aortic root and the pos-
sibility of breaking off calcific debris, which could lead to a
higher postoperative stroke rate. Perhaps you could comment
on that.
Dr Rao. We do not have any experience with the Freestyle
valve, but we are certainly concerned with the placement of
an SPV bioprosthesis in the calcific aortic root because of the
potential for a paravalvular leak. Using a Freestyle valve with
a mini-root replacement may obviate that concern; however,
this entails a more complicated procedure with higher mor-
bidity and mortality in the average surgeon’s hands.
Dr Sintek. The other advantage with the Freestyle valve is
that it can be trimmed down to within just a couple of mil-
limeters of the anulus, so that the distal suture line is really
actually just above the patient’s anulus, which can be decal-
cified as the anulus is being prepared for the proximal suture
line. That indeed is what we have done in that situation.
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